论文部分内容阅读
目的:探讨痰热清注射液对急性期的阻塞性肺气肿患者的疗效。方法:选择在我院就诊的符合临床诊断标准病情处于急性期的阻塞性肺气肿患者88例作为本次研究对象,以治疗方式为依据将研究对象分成对照组和治疗组,每组44例。采用孟鲁司特钠对对照组患者实施治疗;采用孟鲁司特钠与痰热清注射液联合对治疗组患者实施治疗。对比两组患者在用药前后炎症细胞因子水平的改善幅度、呼吸功能恢复正常时间、治疗总时间、在治疗期间不良反应发生情况以及药物治疗效果。结果:治疗组患者在用药前后炎症细胞因子水平的改善幅度明显大于对照组(P<0.05);呼吸功能恢复正常时间和肺气肿疾病药物治疗总时间明显短于对照组(P<0.05);在肺气肿疾病治疗期间出现的药物不良反应例数明显少于对照组(P<0.05);阻塞性肺气肿的药物治疗效果明显优于对照组(P<0.05)。结论:应用痰热清注射液对病情处于急性期阶段的阻塞性肺气肿患者实施治疗的临床效果非常明显。
Objective: To investigate the efficacy of Tanreqing injection in patients with obstructive pulmonary emphysema in acute phase. Methods: Eighty-eight patients with obstructive pulmonary emphysema whose clinical diagnosis was in our hospital were selected as the object of study. The subjects were divided into control group and treatment group on the basis of treatment mode, 44 cases in each group . The patients in the control group were treated with montelukast sodium. Patients in the treatment group were treated with montelukast sodium and Tanreqing injection. The improvement rate of inflammatory cytokines, resumption of normal respiratory function, the total time of treatment, the adverse reactions during treatment and the effect of drug treatment were compared between the two groups before and after treatment. Results: The improvement of inflammatory cytokines levels in the treatment group before and after treatment were significantly greater than those in the control group (P <0.05). The total time of resumption of respiratory function and emphysema were significantly shorter than that of the control group (P <0.05). The number of adverse drug reactions occurred during the treatment of emphysema was significantly less than that of the control group (P <0.05). The therapeutic effect of obstructive emphysema was significantly better than that of the control group (P <0.05). Conclusion: The clinical effect of Tanreqing injection for patients with obstructive pulmonary emphysema who are in the acute phase is very obvious.